Sign Up
OverviewAPI
Bragar Eagel & Squire, P.C. is investigating potential claims against Axsome Therapeutics, Inc. for alleged deficient CMC practices. This follows a class action complaint citing overstatement of regulatory and commercial prospects, resulting in a major stock price drop post FDA response.

Ask a question